Inozyme Pharma Inc (INZY) concluded trading on Wednesday at a closing price of $3.95, with 5.93 million shares of worth about $23.42 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 47.03% during that period and on Wednesday the price remained unchanged. Currently the company’s common shares owned by public are about 64.47M shares, out of which, 43.37M shares are available for trading.
Stock saw a price change of 0.13% in past 5 days and over the past one month there was a price change of 310.06%. Year-to-date (YTD), INZY shares are showing a performance of 42.78% which decreased to -13.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.72 but also hit the highest price of $6.24 during that period. The average intraday trading volume for Inozyme Pharma Inc shares is 1.92 million. The stock is currently trading 67.73% above its 20-day simple moving average (SMA20), while that difference is up 161.72% for SMA50 and it goes to 36.21% higher than SMA200.
Inozyme Pharma Inc (NASDAQ: INZY) currently have 64.47M outstanding shares and institutions hold larger chunk of about 59.45% of that.
The stock has a current market capitalization of $255.34M and its 3Y-monthly beta is at 2.32. It has posted earnings per share of -$1.68 in the same period. It has Quick Ratio of 2.19 while making debt-to-equity ratio of 1.48. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INZY, volatility over the week remained 0.16% while standing at 24.69% over the month.
Analysts are in expectations that Inozyme Pharma Inc (INZY) stock would likely to be making an EPS of -0.32 in the current quarter, while forecast for next quarter EPS is -0.27 and it is -0.98 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.36 which is -0.29 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.44 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 11.66% while it is estimated to increase by 20.03% in next year. EPS is likely to grow at an annualized rate of 21.72% for next 5-years, compared to annual growth of -13.98% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on December 12, 2024 offering an Outperform rating for the stock and assigned a target price of $26 to it. Coverage by Stifel stated Inozyme Pharma Inc (INZY) stock as a Buy in their note to investors on September 12, 2024, suggesting a price target of $16 for the stock. On August 13, 2024, Jefferies Resumed their recommendations, while on May 30, 2024, Wells Fargo Initiated their ratings for the stock with a price target of $14. Stock get a Buy rating from Jefferies on March 23, 2023.
